Catalyst Dossier · compiled by CeliA 🧫

BRISTOL MYERS SQUIBB CO (CELG-RI)

Biotechnology · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-09-05 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-09-05 (est.)Phase 2 · BMS-986490imp 7/10
2026-09-30 (est.)Phase 3 · Sorafenibimp 9/10
2026-09-30 (est.)Phase 2 · BMS-986449imp 7/10
2026-10-06 (est.)Phase 3 · BMS-986278imp 9/10
2026-10-12 (est.)Phase 2 · CC-92480imp 7/10
2026-11-09 (est.)Phase 3 · Sorafenibimp 9/10
2026-11-18 (est.)Phase 3 · Deucravacitinibimp 9/10
2026-12-14 (est.)Phase 2 · BMS-986435imp 7/10

Pipeline

Asset	Phase	Indication
BMS-986249	Phase 2	Advanced Cancer
BMS-754807	Phase 2	Breast Cancer
Aurexis®	Phase 2	Staphylococcus Aureus Bacteremia
Atazanavir/Ritonavir	Phase 3	HIV
Vitamin K Antagonist (VKA)	Phase 2	Thrombosis
Cetuximab	Phase 3	Squamous Cell Carcinoma of the Head and Neck
Letrozole	Phase 2	Metastatic Breast Cancer
CXL-1020	Phase 2	Heart Failure
Stavudine	Phase 3	HIV Infections
Oral Taxane	Phase 2	Non-small Cell Lung Cancer
BMS-986253	Phase 2	Cancer
BMS-986322	Phase 2	Psoriasis
Doxorubicin	Phase 2	Hodgkin Disease
Mavacamten	Phase 3	Cardiomyopathy, Hypertrophic
BMS-986490	Phase 2	Advanced Solid Tumors
Abatacept	Phase 3	Rheumatoid Arthritis
MYK-491	Phase 2	Heart Failure With Reduced Ejection Fraction
Entecavir	Phase 3	Hepatitis B, Chronic
Cisplatin	Phase 3	Non Small Cell Lung Cancer
Carboplatin	Phase 3	Pediatric Solid Tumors

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CELG-RI (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.